Program
napazimone
Also written as “KL1333”, “Napazimone” and “KL1333 25 mg”.
Its studies are mostly in Mitochondrial Diseases · MELAS Syndrome · Muscular Diseases, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pharming Group | 42 open or running | phase 2since Dec 6, 2022 | Mar 19, 2019 | Oct 2027phase 2 · NCT05650229 |
| Yungjin Pharm. | 10 open or running | phase 1since Feb 5, 2017 | Feb 5, 2017 | none ahead |
Also a collaborator on its studies: icon-plc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 5, 2017First study: phase 1 study in MELAS SyndromeNew to Yungjin Pharm.Yungjin Pharm. · NCT03056209 · 60 enrolled · Korea, Republic of
- Mar 19, 2019Pharming Group's first study: phase 1 study in Mitochondrial DiseasesNew to Pharming GroupPharming Group · NCT03888716 · 72 enrolled · United Kingdom
- Nov 13, 2020Phase 1 study in Mitochondrial DiseasesPharming Group · NCT04643249 · 14 enrolled · United Kingdom
- Dec 6, 2022Phase 2 study in Muscular DiseasesPharming Group · NCT05650229 · 180 planned · United States, Australia, Belgium and more
- Feb 24, 2026Phase 2 study in Mitochondrial DiseasesPharming Group · NCT07514338 · 140 planned · United States, Belgium, Czechia and more
Ahead
- Oct 2027Primary completion: phase 2 study in Muscular DiseasesPharming Group · NCT05650229
- Mar 31, 2029Primary completion: phase 2 study in Mitochondrial DiseasesPharming Group · NCT07514338
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07514338Mitochondrial Diseases · United States, Belgium, Czechia and more | 2 | Recruiting | Pharming Group | Mar 31, 2029 | 140 |
| NCT05650229Muscular Diseases · United States, Australia, Belgium and more | 2 | Recruiting | Pharming Group | Oct 2027 | 180 |
| NCT04643249Mitochondrial Diseases · United Kingdom | 1 | Completed | Pharming Group | Dec 17, 2020 | 14 |
| NCT03888716Mitochondrial Diseases · United Kingdom | 1 | Completed | Pharming Group | Mar 16, 2021 | 72 |
| NCT03056209MELAS Syndrome · Korea, Republic of | 1 | Completed | Yungjin Pharm. | Apr 16, 2018 | 60 |
How it is read
Names in the registry
- “KL1333”, 3 entries
- “Napazimone”, 1 entry
- “KL1333 25 mg”, 1 entry
- “KL1333 50 mg”, 1 entry
- “KL1333 100 mg”, 1 entry
Conditions, from the studies’ own filings
- Mitochondrial Diseases, 2 studies
- MELAS Syndrome, 2 studies
- Muscular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.